The First Affiliated Hospital With Nanjing Medical University

This study tests whether dihydroartemisinin, a drug used for malaria, can safely reduce liver fat in adults with Metabolic Associated Fatty Liver Disease (MAFLD). About 30 participants aged 18 to 45 will take the drug three times daily for 12 weeks. The main goal is to measure ch…

This phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycle…

This study tests a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (gemcitabine and nab-paclitaxel) as a first treatment for people with biliary tract cancer that cannot be removed by surgery. The goal is to see if this combo can shrink tumors a…

This phase 2 trial tests a new approach for people with locally advanced rectal cancer. Participants first receive a short course of radiation, followed by a combination of immunotherapy (sintilimab and IL-2) and chemotherapy (CAPOX). The goal is to see if this treatment can make…

This study tests whether a lower dose of short-course radiotherapy, combined with chemotherapy and two immune-boosting drugs, works as well as the standard radiation dose for locally advanced rectal cancer. About 122 adults will be randomly assigned to one of two radiation doses,…

This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy after surgery can help prevent high-risk triple-negative breast cancer from coming back. About 59 women with this aggressive cancer type will receive the combination treatment, follo…

This study tests a new combination of drugs for people with a specific type of untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if the treatment can keep the cancer from coming back for at least two years. About 35 participants will receive six cycles of the dr…

This early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to ch…

This study compares a newer pacing method called conduction system pacing (CSP) with the standard biventricular pacing (BiVP) in heart failure patients who already have a right ventricular pacemaker and need an upgrade. Researchers want to see if CSP is as good as BiVP at improvi…

This study tests whether using focused ultrasound (HIFU) to destroy tumors, with or without an immune-boosting drug (PD-1 inhibitor), before standard chemotherapy can improve outcomes for people with early-stage triple-negative breast cancer. About 58 participants will receive on…

This study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will ha…

This study tests a new heart pacing method (LOT-CRT) against the standard one (BiVP) in 86 heart failure patients with a specific type of heart block. The goal is to see if the new method better preserves heart pumping function. Participants will be followed for at least 6 months…

This study will compare two surgical approaches for breast cancer patients who need a mastectomy (breast removal) and immediate reconstruction. One group will have standard surgery, while the other will use a newer, endoscopic-assisted technique that may involve smaller incisions…

This study tests whether GLP-1 receptor agonists, a class of diabetes medications including semaglutide, can improve heart nerve damage in people with type 2 diabetes. 60 adults will receive either standard care or standard care plus a weekly injection for 6 months. Researchers w…

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy aims to reset the immune system by targeting and removing faulty B cells. About 72 adults will re…

This study tests a new drug called romiplostim N01, given as a weekly shot, against a standard daily shot (rhIL-11) for cancer patients whose platelet counts drop due to treatment. About 88 adults with various cancers and low platelets will be randomly assigned to one of the two …

This study tests whether a 7-day combination of vonoprazan, high-dose amoxicillin, and bismuth can effectively eradicate H. pylori bacteria in the stomach. About 316 adults with a first-time H. pylori infection will be randomly assigned to either the 7-day triple therapy or a sta…

This early study tests a new medicine called SC101, given as a single injection around the kidneys, for people with resistant high blood pressure and moderate to severe chronic kidney disease. The main goal is to check safety, with only 3 participants. Researchers will also monit…

This study tests whether adding an immune-boosting drug (thymosin alpha 1) to standard chemo-immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 participants will receive either the standard treatment or the standard plus thymos…

This study tests whether adding the targeted drug disitamab vedotin to standard chemotherapy (SOX) after surgery can help prevent stomach cancer from coming back in people with HER2-positive stage III disease. About 124 adults who had complete tumor removal with extensive lymph n…

This early-stage study tests whether stem cells from human amniotic fluid can help heal painful skin wounds (calciphylaxis) in people with chronic kidney disease. Nine participants will receive the stem cell treatment, and researchers will measure wound healing and pain levels. T…

This phase 2 trial is testing whether a combination of the immunotherapy drug bemosubaiabimab, the targeted pill anlotinib, plus radiation and chemotherapy can help people with oligometastatic esophageal cancer—cancer that has spread to a few spots. About 28 participants will rec…

This study tests a combination of three drugs (orelabrutinib, rituximab, and lenalidomide) in people with untreated marginal zone lymphoma, a type of blood cancer. The goal is to see if this approach can make tumors disappear completely. About 50 adults with advanced disease will…

This phase 2 trial tests a combination of two drugs—disitamab vedotin and bevacizumab—in 37 people with HER2-low metastatic breast cancer whose disease progressed after prior T-DXd therapy. The goal is to see if the combo can shrink tumors and delay progression. Researchers will …

This phase 2 trial is testing a combination of four drugs (zanubrutinib, rituximab, lenalidomide, and tislelizumab) in 33 people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see how many patients achieve a complete r…

This phase 2 trial is testing a combination of four drugs (PD-1 inhibitor, rituximab, methotrexate, and orelabrutinib) in 50 people with newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this mix can stop the cancer from growing for at least a yea…

This study looks at how safe robotic surgery is for removing gastrointestinal stromal tumors (GISTs) located in hard-to-reach areas of the stomach. About 182 adults with small to medium tumors (2-5 cm) will have the robotic procedure. Researchers will track how many patients stay…

This study is testing whether adding two drugs (anlotinib and a tubulin inhibitor) to standard radiation therapy can help control HER2-negative breast cancer that has spread to the brain. About 39 women aged 18-70 will receive radiation followed by the drug combination. The main …

This study looks at the safety and effectiveness of the immunotherapy drug durvalumab in 25 people with limited-stage small cell lung cancer who have already had chemotherapy and radiation. The drug is given as a follow-up treatment to try to keep the cancer from coming back. Res…

This early-phase study tests a new cell therapy called LVIVO-TaVec200 in 36 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the therapy behaves in the body. Participa…

This study tests whether giving two drugs directly into the spinal fluid can shrink or control breast cancer that has spread to the lining of the brain. It is for people with HER2-positive breast cancer. The drugs are given through a small device placed under the scalp. The goal …

This study looks at whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (SOX) can help prevent stomach cancer from coming back after surgery. It involves 460 adults with a specific type of advanced stomach cancer (PD-L1 positive, stage N3). Participants are…

This early study tests whether a patient's own natural killer (NK) cells, given as infusions, are safe and can help shrink lung nodules. 24 adults with high-risk nodules will receive multiple doses. The main goal is to check for side effects within 28 days, with tumor response as…

This phase 2 trial is testing a combination of two drugs—tislelizumab (an immunotherapy) and anlotinib (a targeted therapy)—as a second-line treatment for people with thymoma or thymic carcinoma whose cancer has progressed after initial chemotherapy. The study will enroll 20 part…

This study tests whether adding venetoclax (a targeted drug) to ongoing BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve deep remission and then stop all treatment. About 79 adults who have been on a BTK inhibitor for at least 6 months and are…

This phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is…

This study tests two different drug combinations for people newly diagnosed with marginal zone lymphoma, a slow-growing blood cancer. One group gets a new targeted therapy (orelabrutinib) plus two other drugs, while the other gets standard chemo-immunotherapy. The goal is to see …

This Phase 2 trial tests a combination of the drug linperlisib plus three older drugs (cyclophosphamide, prednisone, and thalidomide) in 180 adults with non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to see how many patients achieve a complete o…

This study tests a new MRI technique that uses a special iron-based contrast agent (ferumoxytol) to detect calcium buildup in heart arteries. Researchers will compare this method to standard CT scans in 100 adults with known calcified arteries. The goal is to see if the MRI can a…

This study is testing an artificial intelligence system that analyzes routine contrast-enhanced CT scans to detect stomach cancer and determine its stage (how far it has spread). The goal is to help doctors decide the best treatment, such as whether surgery is needed and how much…

This study tests if using ultrasound to push a medicine mix (tranexamic acid and glutathione) deeper into the skin can safely lighten melasma patches. About 35 adults with facial melasma will receive the treatment on one side of their face and a comparison on the other. The goal …

This study tests a personalized sound therapy for people with chronic tinnitus (ringing in the ears lasting over 6 months). Researchers will use each participant's hearing loss and tinnitus pitch to create custom audio signals. The goal is to see if this acoustic stimulation redu…

This study looks at whether changing the oxygen level during embryo growth in IVF can improve the chance of having a healthy, full-term baby. About 980 women undergoing IVF will have their embryos grown in either a constant 5% oxygen or a sequential 5% then 2% oxygen environment.…

This study will follow 1000 pregnant women to find what raises the risk of gestational diabetes and create a tool to predict it early. Then, some women will try a personalized health plan (GLOW plan) to see if it improves blood sugar control. The goal is to reduce short- and long…

This study aims to improve how doctors measure disease activity in people with axial spondyloarthritis (axSpA), a type of inflammatory arthritis affecting the spine and joints. Researchers will use whole-body MRI scans and machine learning to create a new assessment model. The st…